Chemical formula: C₁₄H₁₂O₂ Molecular mass: 212.244 g/mol PubChem compound: 3332
Since the safety of felbinac in human pregnancy has not been established, it is not recommended for use in these circumstances. As with other non-steroidal anti-inflammatory agents which inhibit prostaglandin synthesis, dystocia and delayed parturition have been observed in animal studies when felbinac is administered late in pregnancy.
None.
A low incidence of mild local irritation, erythema, dermatitis, pruritis and paraesthesia which recovers spontaneously upon cessation of treatment may be expected with this medicine.
Systemic side effects are rare; hypersensitivity reactions such as widespread rashes including urticaria and bronchospasm have been reported with felbinac. Gastrointestinal disturbances have been reported occasionally.
Skin photosensitivity has been reported.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
